Tse Hsien Koh
Singapore General Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Tse Hsien Koh.
Nature Genetics | 2013
Miao He; Fabio Miyajima; Paul C. Roberts; Louise Ellison; Derek Pickard; Melissa J. Martin; Thomas Richard Connor; Simon R. Harris; Derek Fairley; Kathleen B. Bamford; Stephanie D'Arc; Jonathan S. Brazier; Derek J. Brown; John E. Coia; Gill Douce; Dale N. Gerding; Heejung Kim; Tse Hsien Koh; Haru Kato; Mitsutoshi Senoh; Tom Louie; Stephen L. Michell; Emma Butt; Sharon J. Peacock; Nick Brown; Thomas V. Riley; Glen Songer; Mark H. Wilcox; Munir Pirmohamed; Ed J. Kuijper
Epidemic C. difficile (027/BI/NAP1) has rapidly emerged in the past decade as the leading cause of antibiotic-associated diarrhea worldwide. However, the key events in evolutionary history leading to its emergence and the subsequent patterns of global spread remain unknown. Here, we define the global population structure of C. difficile 027/BI/NAP1 using whole-genome sequencing and phylogenetic analysis. We show that two distinct epidemic lineages, FQR1 and FQR2, not one as previously thought, emerged in North America within a relatively short period after acquiring the same fluoroquinolone resistance–conferring mutation and a highly related conjugative transposon. The two epidemic lineages showed distinct patterns of global spread, and the FQR2 lineage spread more widely, leading to healthcare-associated outbreaks in the UK, continental Europe and Australia. Our analysis identifies key genetic changes linked to the rapid transcontinental dissemination of epidemic C. difficile 027/BI/NAP1 and highlights the routes by which it spreads through the global healthcare system.
Antimicrobial Agents and Chemotherapy | 2015
Scott A. Cunningham; Nicolynn C. Cole; Peggy C. Kohner; Sanjay R. Menon; Kevin M. Krause; Kelly A. Harris; Partha Pratim De; Tse Hsien Koh; Robin Patel
ABSTRACT Among 177 carbapenemase-producing Gram-negative bacilli (108 KPC, 32 NDM, 11 IMP, 8 OXA-48, 4 OXA-181, 2 OXA-232, 5 IMI, 4 VIM, and 3 SME producers), aztreonam-avibactam was active against all isolates except two NDM producers with elevated MICs of 8/4 and 16/4 mg/liter; ceftazidime-avibactam was active against all KPC-, IMI-, SME-, and most OXA-48 group-producing isolates (93%) but not metallo-β-lactamase producers. Among older and contemporary antimicrobials, the most active were colistin, tigecycline, and fosfomycin, with overall susceptibilities of 88%, 79%, and 78%, respectively.
Infection and Immunity | 2014
Pradeep Bist; Neha Dikshit; Tse Hsien Koh; Alessandra Mortellaro; Thuan Tong Tan; Bindu Sukumaran
ABSTRACT Acinetobacter baumannii is a major extensively drug-resistant lethal human nosocomial bacterium. However, the host innate immune mechanisms controlling A. baumannii are not well understood. Although viewed as an extracellular pathogen, A. baumannii can also invade and survive intracellularly. However, whether host innate immune pathways sensing intracellular bacteria contribute to immunity against A. baumannii is not known. Here, we provide evidence for the first time that intracellular antibacterial innate immune receptors Nod1 and Nod2, and their adaptor Rip2, play critical roles in the sensing and clearance of A. baumannii by human airway epithelial cells in vitro. A. baumannii infection upregulated Rip2 expression. Silencing of Nod1, Nod2, and Rip2 expression profoundly increased intracellular invasion and prolonged the multiplication and survival of A. baumannii in lung epithelial cells. Notably, the Nod1/2-Rip2 axis did not contribute to the control of A. baumannii infection of human macrophages, indicating that they play cell type-specific roles. The Nod1/2-Rip2 axis was needed for A. baumannii infection-induced activation of NF-κB but not mitogen-activated protein kinases. Moreover, the Nod1/2-Rip2 axis was critical to induce optimal cytokine and chemokine responses to A. baumannii infection. Mechanistic studies showed that the Nod1/2 pathway contributed to the innate control of A. baumannii infection through the production of β-defensin 2 by airway epithelial cells. This study revealed new insights into the immune control of A. baumannii and may contribute to the development of effective immune therapeutics and vaccines against A. baumannii.
Antimicrobial Agents and Chemotherapy | 2016
Thai-Hoang Le; Charmaine Ng; Hongjie Chen; Xin Zhu Yi; Tse Hsien Koh; Timothy Barkham; Zhi Zhou; Karina Yew-Hoong Gin
ABSTRACT Wastewater discharged from clinical isolation and general wards at two hospitals in Singapore was examined to determine the emerging trends of antibiotic resistance (AR). We quantified the concentrations of 12 antibiotic compounds by analysis using liquid chromatography-tandem mass spectrometry (LC-MS/MS), antibiotic-resistant bacteria (ARB), the class 1 integrase gene (intI1), and 16 antibiotic resistance genes (ARGs) that confer resistance to 10 different clinically relevant antibiotics. A subset of 119 antibiotic-resistant isolates were phylogenetically classified and tested for the presence of ARGs encoding resistance to β-lactam antibiotics (blaNDM, blaKPC, blaSHV, blaCTX-M), amikacin [aac(6′)-Ib], co-trimoxazole (sul1, sul2, dfrA), ciprofloxacin (qnrA, qnrB), and the intI1 gene. Among these resistant isolates, 80.7% were detected with intI1 and 66.4% were found to carry at least 1 of the tested ARGs. Among 3 sampled locations, the clinical isolation ward had the highest concentrations of ARB and the highest levels of ARGs linked to resistance to β-lactam (blaKPC), co-trimoxazole (sul1, sul2, dfrA), amikacin [aac(6′)-Ib], ciprofloxacin (qnrA), and intI1. We found strong positive correlations (P < 0.05) between concentrations of bacteria resistant to meropenem, ceftazidime, amikacin, co-trimoxazole, and ciprofloxacin and abundances of blaKPC, aac(6′)-Ib, sul1, sul2, dfrA, qnrA, and intI1 genes.
Antimicrobial Agents and Chemotherapy | 2015
Tze Peng Lim; Rick Twee-Hee Ong; Pei-Yun Hon; Jane Hawkey; Kathryn E. Holt; Tse Hsien Koh; Micky Lo-Ngah Leong; Jocelyn Qi-Min Teo; Thean Yen Tan; Mary Mah-Lee Ng; Li Yang Hsu
ABSTRACT We studied polymyxin B resistance in 10 pairs of clinical Acinetobacter baumannii isolates, two of which had developed polymyxin B resistance in vivo. All polymyxin B-resistant isolates had lower growth rates than and substitution mutations in the lpx or pmrB gene compared to their parent isolates. There were significant differences in terms of antibiotic susceptibility and genetic determinants of resistance in A. baumannii isolates that had developed polymyxin B resistance in vivo compared to isolates that had developed polymyxin B resistance in vitro.
Antimicrobial Agents and Chemotherapy | 2013
Pei Yun Hon; Kian Sing Chan; Matthew T. G. Holden; Simon R. Harris; Thean Yen Tan; Yan-Bing Zu; Prabha Krishnan; Lynette Oon; Tse Hsien Koh; Li Yang Hsu
Espedido and coworkers found that up to 38.7% of methicillin-resistant Staphylococcus aureus (MRSA) clonal group ST239-MRSA-III strains in a Sydney hospital carried an arginine catabolic mobile element (ACME) type II variant that inserted between orfX and the staphylococcal cassette chromosome mec
Scandinavian Journal of Infectious Diseases | 2012
Jaime Mei Fong Chien; Tse Hsien Koh; Kian Sing Chan; Thuan Heng Charles Chuah; Thuan Tong Tan
Abstract The rapid emergence of novel multidrug-resistant organisms coupled with the slow development of new antibiotics is of great concern. With the discovery of New Delhi metallo-beta-lactamase 1 (NDM-1)-producing Klebsiella pneumoniae, clinicians are faced with problems in the treatment of infections caused by this multidrug-resistant organism. Therapeutic experiences are limited. We share our experience of the successful treatment of a febrile neutropenic patient with NDM-1-producing K. pneumoniae bacteraemia.
Clinical Infectious Diseases | 2017
Kalisvar Marimuthu; Indumathi Venkatachalam; Wei Xin Khong; Tse Hsien Koh; Benjamin Pei Zhi Cherng; My Van La; Partha Pratim De; Prabha Krishnan; Thean Yen Tan; Raymond Fong Kok Choon; Surinder Pada; Choong Weng Lam; Say Tat Ooi; Rama Narayana Deepak; Nares Smitasin; Eng Lee Tan; Jia Jun Lee; Asok Kurup; Barnaby Young; Nancy Tee Wen Sim; Koh Cheng Thoon; Dale Fisher; Moi Lin Ling; Brenda Ang Sze Peng; Yik-Ying Teo; Li Yang Hsu; Raymond T.P. Lin; Rick Twee-Hee Ong; Jeanette Teo; Oon Tek Ng
BackgroundnSince 2010, the incidence of carbapenem-resistant Enterobacteriaceae (CRE) has been increasing in Singapore. We analyzed the clinical and molecular epidemiology of CRE among adult inpatients in Singapore.nnnMethodsnQuarterly incidence of unique subjects (per 100000 patient-days) with positive clinical and surveillance cultures for CRE were estimated based on mandatory data submitted to the National Public Health Laboratory by public hospitals between 2010 and 2015. CRE-positive adult inpatients were prospectively recruited from 6 public sector hospitals between December 2013 and April 2015. Subjects answered a standardized epidemiologic questionnaire and provided samples for this study. Further clinical information was extracted from subjects electronic medical records. Whole-genome sequencing was performed on study isolates to determine transmission clusters.nnnResultsnIncidence of CRE clinical cultures among adult inpatients plateaued from 2013 (range: 7.73 to 10.32 per 100000 patient-days) following an initial increase between 2010 and end-2012. We prospectively recruited 249 subjects. Their median age was 65 years, 108 (43%) were female, and 161 (64.7%) had carbapenemase-producing Enterobacteriaceae (CPE). On multivariate analysis, prior carbapenem exposure (OR: 3.23; 95% CI: 1.67-6.25) and hematological malignancies (OR: 2.85; 95% CI: 1.10-7.41) were associated with non-carbapenemase-producing CRE (NCPE) (n = 88) compared with CPE (n = 161) subjects. Among 430 CRE isolates from the 249 subjects, 307(71.3%) were CPE, of which 154(50.2%) were blaKPC-positive, 97(31.6%) blaNDM-positive, and 42 (13.7%) blaOXA-positive. Klebsiella pneumoniae (n = 180, 41.9%), Escherichia coli (n = 129, 30.0%) and Enterobacter cloacae (n = 62, 14.4%) were the main Enterobacteriaceae species. WGS (n = 206) revealed diverse bacterial strain type (STs). The predominant blaKPC-positive plasmid was pHS102707 (n = 62, 55.4%) and the predominant blaNDM-positive plasmid was pNDM-ECS01 (n = 46, 48.9%). Five transmission clusters involving 13 subjects were detected.nnnConclusionsnClinical CRE trend among adult inpatients showed stabilization following a rapid rise since introduction in 2010 potentially due to infection prevention measures and antimicrobial stewardship. More work is needed on understanding CPE transmission dynamics.
Clinical Infectious Diseases | 2017
Shirin Kalimuddin; Swaine L. Chen; Cindy Lim; Tse Hsien Koh; Thean Yen Tan; Michelle Kam; Christopher W. Wong; Kurosh S. Mehershahi; Man Ling Chau; Lee Ching Ng; Wen Ying Tang; Hishamuddin Badaruddin; Jeanette Teo; Anucha Apisarnthanarak; Nuntra Suwantarat; Margaret Ip; Matthew T. G. Holden; Li Yang Hsu; Timothy Barkham
BackgroundnStreptococcus agalactiae (group B Streptococcus [GBS]) has not been described as a foodborne pathogen. However, in 2015, a large outbreak of severe invasive sequence type (ST) 283 GBS infections in adults epidemiologically linked to the consumption of raw freshwater fish occurred in Singapore. We attempted to determine the scale of the outbreak, define the clinical spectrum of disease, and link the outbreak to contaminated fish.nnnMethodsnTime-series analysis was performed on microbiology laboratory data. Food handlers and fishmongers were screened for enteric carriage of GBS. A retrospective cohort study was conducted to assess differences in demographic and clinical characteristics of patients with invasive ST283 and non-ST283 infections. Whole-genome sequencing was performed on human and fish ST283 isolates from Singapore, Thailand, and Hong Kong.nnnResultsnThe outbreak was estimated to have started in late January 2015. Within the study cohort of 408 patients, ST283 accounted for 35.8% of cases. Patients with ST283 infection were younger and had fewer comorbidities but were more likely to develop meningoencephalitis, septic arthritis, and spinal infection. Of 82 food handlers and fishmongers screened, none carried ST283. Culture of 43 fish samples yielded 13 ST283-positive samples. Phylogenomic analysis of 161 ST283 isolates from humans and fish revealed they formed a tight clade distinguished by 93 single-nucleotide polymorphisms.nnnConclusionsnST283 is a zoonotic GBS clone associated with farmed freshwater fish, capable of causing severe disease in humans. It caused a large foodborne outbreak in Singapore and poses both a regional and potentially more widespread threat.
Antimicrobial Agents and Chemotherapy | 2017
Yiying Cai; Tze-Peng Lim; Jocelyn Qi-Min Teo; Suranthran Sasikala; Eric Chun Yong Chan; Yan Jun Hong; Winnie Lee; Thean Yen Tan; Thuan Tong Tan; Tse Hsien Koh; Li Yang Hsu; Andrea Lay-Hoon Kwa
ABSTRACT Polymyxin B-based combinations have emerged as a mainstay treatment against carbapenem-resistant Escherichia coli (CREC). We investigated the activity of polymyxin B-based two-antibiotic combinations against CREC using time-kill studies (TKS) and validated the findings in a hollow-fiber infection model (HFIM). TKS were conducted using 5 clinical CREC strains at 5 log10 CFU/ml against 10 polymyxin B-based two-antibiotic combinations at maximum clinically achievable concentrations. HFIMs simulating dosing regimens with polymyxin B (30,000U/kg/day) and tigecycline (100 mg every 12 h) alone and in combination were conducted against two CREC strains at 5 log10 CFU/ml over 120 h. Emergence of resistance was quantified using antibiotic-containing media. Phenotypic characterization (growth rate and stability of resistant phenotypes) of the resistant isolates was performed. All five CREC strains harbored carbapenemases. Polymyxin B and tigecycline MICs ranged from 0.5 mg/liter to 2 mg/liter and from 0.25 mg/liter to 8 mg/liter, respectively. All antibiotics alone did not have bactericidal activity at 24 h in the TKS, except for polymyxin B against two strains. In combination TKS, only polymyxin B plus tigecycline demonstrated both bactericidal activity and synergy in two out of five strains. In the HFIM, polymyxin B alone was bactericidal against both CREC strains before regrowth was observed at 8 h. Phenotypically stable polymyxin B-resistant mutants were observed for both strains, with a reduced growth rate observed in one strain. Tigecycline alone resulted in a slow reduction in bacterial counts. Polymyxin B plus tigecycline resulted in rapid and sustained bactericidal killing up to 120 h. Polymyxin B plus tigecycline is a promising combination against CREC. The clinical relevance of our results warrants further investigations.